1-12 of 12
Dongsheng Tu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial

Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Daniel J. Renouf, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3189–3199.
https://doi.org/10.1158/1078-0432.CCR-24-0268
Published: 01 August 2024
View article titled, Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Open the PDF for Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial in another window
Includes: Supplementary data
Journal Articles

Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials

Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, Dongsheng Tu, Stephanie Y. Brule, Rachel Goodwin, Derek J. Jonker, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Lillian Siu, Jeremy Shapiro, John Simes, Sharlene Gill, Chris J. O'Callaghan, Jonathan M. Loree
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1121–1130.
https://doi.org/10.1158/1078-0432.CCR-23-3275
Published: 15 March 2024
View article titled, Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Open the PDF for Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials

Karama Asleh, Dongsheng Tu, Dongxia Gao, Vivien Bramwell, Mark N. Levine, Kathleen I. Pritchard, Lois E. Shepherd, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6570–6579.
https://doi.org/10.1158/1078-0432.CCR-21-1942
Published: 01 December 2021
View article titled, Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Open the PDF for Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 52–59.
https://doi.org/10.1158/1078-0432.CCR-20-2710
Published: 04 January 2021
View article titled, Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Open the PDF for Expanded Low Allele Frequency <em>RAS</em> and <em>BRAF</em> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial in another window
Includes: Supplementary data
Journal Articles

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221

Anna V. Tinker, Holger W. Hirte, Diane Provencher, Marcus Butler, Heather Ritter, Dongsheng Tu, Hatem A. Azim, Jr, Paulo Paralejas, Nathalie Grenier, Shirley-Ann Hahn, Janelle Ramsahai, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6052–6060.
https://doi.org/10.1158/1078-0432.CCR-19-0298
Published: 15 October 2019
View article titled, Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Open the PDF for Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 in another window
Includes: Supplementary data
Journal Articles

Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer

Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A. Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J. Price, Niall C. Tebbutt, Jeremy D. Shapiro, G. Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E. Shepherd, Derek J. Jonker, Christopher J. O'Callaghan, John R. Zalcberg, Christos S. Karapetis, Alexander Dobrovic
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2435–2444.
https://doi.org/10.1158/1078-0432.CCR-15-0414
Published: 12 May 2016
View article titled, Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Open the PDF for Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

Christos S. Karapetis, Derek Jonker, Manijeh Daneshmand, Jennifer E. Hanson, Christopher J. O'Callaghan, Celia Marginean, John R. Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy J. Price, Jeremy D. Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, Ursula Lee, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer, for the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (3): 744–753.
https://doi.org/10.1158/1078-0432.CCR-13-0606
Published: 02 February 2014
View article titled, <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
Open the PDF for <em>PIK3CA, BRAF</em>, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 in another window
Journal Articles

A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

Stephen K. Chia, Vivien H. Bramwell, Dongsheng Tu, Lois E. Shepherd, Shan Jiang, Tammi Vickery, Elaine Mardis, Samuel Leung, Karen Ung, Kathleen I. Pritchard, Joel S. Parker, Philip S. Bernard, Charles M. Perou, Matthew J. Ellis, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4465–4472.
https://doi.org/10.1158/1078-0432.CCR-12-0286
Published: 14 August 2012
View article titled, A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
Open the PDF for A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen in another window
Includes: Supplementary data
Journal Articles

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen K. Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri Davies, Inge J. Stijleman, Carole Davis, Mark T.W. Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2402–2412.
https://doi.org/10.1158/1078-0432.CCR-11-2956
Published: 16 April 2012
View article titled, Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Open the PDF for Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Alternate Endpoints for Screening Phase II Studies

Neesha Dhani, Dongsheng Tu, Daniel J. Sargent, Lesley Seymour, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1873–1882.
https://doi.org/10.1158/1078-0432.CCR-08-2034
Published: 16 March 2009
View article titled, Alternate Endpoints for Screening Phase II Studies
Open the PDF for Alternate Endpoints for Screening Phase II Studies in another window
Journal Articles

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

Kim N. Chi, Lillian L. Siu, Hal Hirte, Sebastien J. Hotte, Jennifer Knox, Christian Kollmansberger, Martin Gleave, Emma Guns, Jean Powers, Wendy Walsh, Dongsheng Tu, Elizabeth Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 833–839.
https://doi.org/10.1158/1078-0432.CCR-07-1310
Published: 01 February 2008
View article titled, A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
Open the PDF for A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer in another window
Journal Articles

Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval

John Goffin, Stefan Baral, Dongsheng Tu, Dora Nomikos, Lesley Seymour
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5928–5934.
https://doi.org/10.1158/1078-0432.CCR-05-0130
Published: 22 August 2005
View article titled, Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
Open the PDF for Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval in another window